Piper Jaffray analyst Joseph Catanzaro kept his Overweight rating and $14 price target on Ocular Therapeutix after its R&D day highlighting the company’s preparations for a mid-2019 Dextenza launch as well as the overall breadth of the hydrogel platform. The analyst believes that while Dextenza gives Ocular Therapeutix a “nice foundation”, the company also has “opportunities to expand in post-ophthalmic surgery, glaucoma, dry eye, retinal disease, as well as sinusitis,osteoarthritis and post-op incisional pain.” Catanzaro speculates that Ocular Therapeutix could file up to 4 Investigational New Drug submissions per year.
https://thefly.com/landingPageNews.php?id=2885847
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.